» Articles » PMID: 26245865

Orienting Patients to Greater Opioid Safety: Models of Community Pharmacy-based Naloxone

Overview
Journal Harm Reduct J
Publisher Biomed Central
Specialties Pharmacology
Psychiatry
Date 2015 Aug 7
PMID 26245865
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

The leading cause of adult injury death in the U.S.A. is drug overdose, the majority of which involves prescription opioid medications. Outside of the U.S.A., deaths by drug overdose are also on the rise, and overdose is a leading cause of death for drug users. Reducing overdose risk while maintaining access to prescription opioids when medically indicated requires careful consideration of how opioids are prescribed and dispensed, how patients use them, how they interact with other medications, and how they are safely stored. Pharmacists, highly trained professionals expert at detecting and managing medication errors and drug-drug interactions, safe dispensing, and patient counseling, are an under-utilized asset in addressing overdose in the U.S. and globally. Pharmacies provide a high-yield setting where patient and caregiver customers can access naloxone-an opioid antagonist that reverses opioid overdose-and overdose prevention counseling. This case study briefly describes and provides two US state-specific examples of innovative policy models of pharmacy-based naloxone, implemented to reduce overdose events and improve opioid safety: Collaborative Pharmacy Practice Agreements and Pharmacy Standing Orders.

Citing Articles

Evaluation of an emergency department-based approach to reduce subsequent opioid overdoses.

Reed E, Papp J, Oh Y, LeVine K, Tarabichi Y, Bastian E J Am Coll Emerg Physicians Open. 2024; 5(5):e13304.

PMID: 39445120 PMC: 11496383. DOI: 10.1002/emp2.13304.


Investigating the complexity of naloxone distribution: Which policies matter for pharmacies and potential recipients.

Smart R, Powell D, Pacula R, Peet E, Abouk R, Davis C J Health Econ. 2024; 97:102917.

PMID: 39043099 PMC: 11392605. DOI: 10.1016/j.jhealeco.2024.102917.


Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties.

Cerda M, Hamilton A, Hyder A, Rutherford C, Bobashev G, Epstein J Epidemiology. 2024; 35(3):418-429.

PMID: 38372618 PMC: 11495844. DOI: 10.1097/EDE.0000000000001703.


Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs.

Tsui J, Gojic A, Pierce K, Tung E, Connolly N, Radick A Drug Alcohol Depend Rep. 2024; 10:100213.

PMID: 38261893 PMC: 10796962. DOI: 10.1016/j.dadr.2023.100213.


Identifying Prescription-Opioid-Related Risks Using Prescription Drug Monitoring Programs' Algorithms and Clinical Screening Tools.

Picco L, Jung M, Cangadis-Douglass H, Lam T, Nielsen S Pharmacy (Basel). 2023; 11(5).

PMID: 37888509 PMC: 10609676. DOI: 10.3390/pharmacy11050164.


References
1.
Sporer K . Acute heroin overdose. Ann Intern Med. 1999; 130(7):584-90. DOI: 10.7326/0003-4819-130-7-199904060-00019. View

2.
Doucette W, McDonough R . Beyond the 4Ps: using relationship marketing to build value and demand for pharmacy services. J Am Pharm Assoc (Wash). 2002; 42(2):183-93; quiz 193-4. DOI: 10.1331/108658002763508470. View

3.
Coffin P, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D . Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health. 2003; 80(2):288-90. PMC: 3456271. DOI: 10.1093/jurban/jtg031. View

4.
Berkowitz B . The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976; 1(3):219-30. DOI: 10.2165/00003088-197601030-00004. View

5.
Seal K, Thawley R, Gee L, Bamberger J, Kral A, Ciccarone D . Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. 2005; 82(2):303-11. PMC: 2570543. DOI: 10.1093/jurban/jti053. View